Rapid diurnal variation of serous retinal detachment during BRAF and MEK inhibitor treatment: A case series

Giorgio Enrico Bravetti; Kevin Muggler; Assma Ben Aissa; Gabriele Thumann; Ariane Malclès

doi:10.1111/aos.16639

Rapid diurnal variation of serous retinal detachment during BRAF and MEK inhibitor treatment: A case series

Acta Ophthalmol. 2024 Jun;102(4):e651-e656. doi: 10.1111/aos.16639. Epub 2024 Jan 18.

Authors

Giorgio Enrico Bravetti¹, Kevin Muggler¹, Assma Ben Aissa², Gabriele Thumann^{1

3}, Ariane Malclès^{1

3}

Affiliations

¹ Department of Ophthalmology, University Hospitals of Geneva, Geneva, Switzerland.
² Department of Oncology, University Hospitals of Geneva, Geneva, Switzerland.
³ Faculty of Medicine of the University of Geneva, UNIGE, Geneva, Switzerland.

PMID: 38235944
DOI: 10.1111/aos.16639

No abstract available

Keywords: BRAF inhibitor; MEK inhibitor; binimetinib; diurnal variation; encorafenib; metastatic melanoma; serous retinal detachment; sub‐retinal fluid.

Publication types

Letter
Case Reports

MeSH terms

Aged
Circadian Rhythm / physiology
Female
Humans
MAP Kinase Kinase 1 / antagonists & inhibitors
Male
Melanoma* / drug therapy
Middle Aged
Protein Kinase Inhibitors* / adverse effects
Proto-Oncogene Proteins B-raf* / antagonists & inhibitors
Retinal Detachment* / diagnosis
Tomography, Optical Coherence / methods

Substances

Proto-Oncogene Proteins B-raf
Protein Kinase Inhibitors
BRAF protein, human
MAP Kinase Kinase 1